Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors

Table 2

Univariate and multivariate analysis for factors associated with PFS.

		Progression-free survival
		Median, 95% CI		HR (95% CI)
Gender	Female	18.2 (0-43.1)
	Male	7.7 (4.9-10.5)	0.067
Age	<60 years	10.3 (5.9-14.7)
	≥60 years	18.8 (0.4-37.2)	0.415
Tobacco smokers	Nonsmoker	27.3 (3.0-51.7)
	Smoker	6.2 (3.8-8.6)	0.163
ECOG PS	0-1	10.3 (0-20.9)
	2+	4.6 (N/R)	0.393
Disease stage	IIIB	N/R (N/R)
	IV	6.5 (4.3-8.6)	0.002	1.6 (0.7-4.0)	0.237
Histological subtype	Carcinoid	NA
	Atypical
	Large cell
	Small cell
Lung metastases	Absent	10.3 (0.2-20.4)
	Present	3.4 (1.1-5.7)	0.349
Bone metastases	Absent	7.8 (1.2-14.4)
	Present	10.3 (3.6-17.0)	0.579
Pleural effusion	Absent	16.9 (4.1-29.7)
	Present	3.4 (0.0-6.8)	<0.001	9.4 (2.3-38.5)	0.02
CNS metastases	Absent	16.9 (6.8-27.1)
	Present	6.5 (4.3-8.6)	0.033	5.2 (1.4-19.3)	0.013
Liver metastases	Absent	15.7 (0.0-32.3)
	Present	6.0 (0.0-11.9)	0.018	3.1 (1.0-9.6)	0.047
Adrenal metastases	Absent	10.3 (3.4-17.2)
	Present	7.8 (7.6-8.1)	0.593
CD47	Negative	7.8 (4.9-10.7)
	Positive	45.7 (0.0-115.3)	0.059	0.7 (0.2-2.5)	0.620